News

Domenica Lorusso, MD, PhD, discusses the rationale behind the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina Gasparetto, MD, on improving these processes.

LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.

Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.

Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic leukemia.

STC-15, an investigational RNA methyltransferase inhibitor, has shown promising clinical activity and an encouraging safety profile across various tumor types.

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 inhibitor–exposed melanoma.

LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, has received FDA orphan drug designation for neuroendocrine cancer treatment.

The FDA approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.

Phase 1 trial findings showed that GD2-CAR T-cell therapy induced significant tumor regressions and neurological improvements in patients with H3K27M-mutant diffuse midline gliomas.

The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported by DREAMM-7 and DREAMM-8 data.

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.

Chunhui Han, PhD, discusses the potential feasibility of the integration of Gallium 68 PSMA-11 in biology-guided radiotherapy for patients with prostate cancer with bony metastases.

The FDA grants approval to revumenib (SNDX-5613) for a subgroup of acute leukemia, and dato-dXd moves into the final stage in NSCLC. We also cover expert updates from the 42nd Annual Chemotherapy Symposium Foundation in CLL, as well as other relevant insights on CML and multiple myeloma treatment.

Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and intermediate-risk non–muscle invasive bladder cancer.

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer treatment.

Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in underserved populations.

A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

Harry Erba, MD, PhD, discusses the specific substudies included in myeloMATCH.

Treatment with pimicotinib achieved a 54% objective response rate at 25 weeks vs 3.2% with placebo in patients with TGCT, significantly reducing stiffness and pain.

The TROPION-Lung12 trial uses a circulating tumor DNA assay to preoperatively screen patients with non–small cell lung cancer for eligibility in post-surgical adjuvant treatment regimens.